StockMarketWire.com - Polarean Imaging said it was due to receive a third and final tranche of $1m as part of its $3m Small Business Innovation Research grant.

The funds would be used to continue a Phase III trial evaluating the use of 129 Xe MRI scanning for children being treated for cystic fibrosis.

The successful conclusion of the trial, which was being performed at Cincinnati Children's Hospital, could provide data to support the routine use of Polarean's 129 Xe MRI imaging technology for more accurate monitoring of lung function during CF treatment, the company said.


At 9:58am: [LON:POLX] Polarean Imaging Plc Ord Gbp0.00037 share price was 0p at 15.75p



Story provided by StockMarketWire.com